Empatica is a full-stack digital health company and an MIT spin-off, with offices in Boston (MA), Milan (Italy), and Seoul (South Korea). We specialize in the development, production, and deployment of medical-grade wearables and digital biomarkers, powered by an AI-driven platform designed for continuous health monitoring and the early detection of medical conditions. The FDA-cleared Empatica Health Monitoring Platform consists of the medical-grade EmbracePlus and EmbraceMini wearables and the world’s largest selection of validated digital measures, enabling thousands of institutional partners to remotely collect patient health data, in trials and studies on sleep, stress, epilepsy, and more. Empatica’s Embrace wearable was the world’s first FDA-cleared smartwatch in neurology to detect epileptic seizures. In 2024, we launched its successor, EpiMonitor, with all of the most loved features of Embrace and even more. EpiMonitor is an all-in-one wearable and smartphone application solution for detecting possible generalized tonic-clonic seizures, alerting caregivers during emergencies, and monitoring epilepsy. It is the only FDA-cleared wrist-worn wearable and app combination for epilepsy monitoring in the US.
Looking for a particular Empatica employee's phone or email?
The Empatica annual revenue was $21 million in 2026.
Matteo Lai is the Co-founder and CEO of Empatica.
109 people are employed at Empatica.
Empatica is based in Boston, Massachusetts.
The NAICS codes for Empatica are [518, 5415, 54, 33, 54151, 51, 541513, 541].
The SIC codes for Empatica are [73, 738, 737].